导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.62% | 1293/4773 |
| 近一周 | -4.34% | 5187/5467 |
| 近一月 | -3.79% | 1366/5421 |
| 近一季 | -5.59% | 1843/5238 |
| 近半年 | -9.07% | 3625/4931 |
| 近一年 | 22.49% | 358/4400 |
| 近两年 | 77.61% | 867/2954 |
| 近三年 | 65.94% | 387/2253 |
| 成立以来 | 118.36% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
8.82% 100/4961 |
-4.29% 3499/5312 |
- - |
- - |
| 2025 | 50.23% 465/4813 |
0.23% 1938/3635 |
4.34% 788/4076 |
28.26% 1275/4524 |
12.00% 146/4813 |
| 2024 | 12.09% 1271/3463 |
14.41% 10/2808 |
-0.39% 757/3014 |
8.14% 2768/3129 |
-9.05% 2898/3463 |
| 2023 | 4.86% 213/2656 |
8.23% 479/2280 |
-3.37% 781/2385 |
3.91% 165/2515 |
-3.51% 713/2655 |
| 2022 | -3.86% 74/2207 |
2.23% 66/1919 |
4.79% 976/2016 |
-4.96% 67/2113 |
-5.57% 1939/2208 |
| 2021 | 41.85% 26/1822 |
4.23% 155/1255 |
11.39% 377/1330 |
29.88% 13/1466 |
-5.93% 1529/1822 |
| 2020 | 17.95% 752/1250 |
-15.59% 986/1028 |
2.96% 956/1067 |
10.86% 502/1164 |
22.43% 43/1184 |
| 2019 | 15.44% 694/1092 |
18.25% 642/754 |
-3.19% 378/804 |
-5.92% 801/850 |
7.18% 471/918 |
| 2018 | -31.86% 509/834 |
- - |
- - |
- - |
-16.29% 633/691 |
| 2017 | 21.00% 171/714 |
- - |
- - |
- - |
- - |
| 2016 | -4.58% 159/605 |
- - |
- - |
- - |
- - |
| 2015 | -8.75% 289/575 |
- - |
- - |
- - |
- - |
| 2014 | 30.81% 160/237 |
- - |
- - |
- - |
- - |
| 2013 | -33.81% 180/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.6144 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6764 | 32.17% |
| 港股医疗 | 0.9539 | 31.90% |
| 港股医疗ETF | 1.4546 | 31.90% |
| 港股通医疗ETF工银 | 0.9639 | 31.81% |
| 港股通医疗ETF华宝 | 0.9752 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4069 | 31.06% |
| 万家中证港股通创新药ETF发起式联接C | 1.4061 | 30.98% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 嘉实中证港股通创新药指数发起式A | 0.8590 | 30.57% |
| 博时上证自然资源ETF VS. 长安沪深300非周期A(740101) |